Acurx Pharmaceuticals (ACXP)
Developing selective-spectrum antibiotics for C. difficile and other Gram-positive infections.
Something off on this page? Send us feedback.
Develops selective-spectrum antibiotics, led by ibezapolstat for C. difficile infection and a preclinical systemic-infection series. It is a pre-revenue, founder-led developer that relies on outsourced clinical and manufacturing work while preparing its lead candidate for late-stage testing.
Develops selective-spectrum small-molecule antibiotics that inhibit bacterial DNA polymerase IIIC. Its lead candidate, ibezapolstat, is an oral treatment in development for Clostridioides difficile infection; a completed mid-stage trial supports a planned international late-stage study. The company also runs a pilot for multiply recurrent infection and a preclinical Pol IIIC series for systemic Gram-positive infections.
Operates through a small Staten Island team that outsources clinical, manufacturing and specialist work. Lead-study work has occurred at U.S. centers, the planned program draws on U.S. and EU regulatory input, and structural research includes a Netherlands university partnership.
Has no approved products or product revenue. Commercialization depends on financing, clinical results, regulatory approval, third-party execution and a sole disclosed supplier for drug substance and finished drug product.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.7M · Total debt $0 · Total assets $11.0M · Shareholders' equity $8.2M
- Revenue
- $0
- Operating income
- −$2.3M
- Net income
- −$2.3M
No dividends on record.
| Institutions22 holders · as of Mar 31, 2026 | 3.48% | 183.2K shares | |
| Insiders6 holders · as of Jan 8, 2025 | 2.20% | 115.8K shares | |
| Otherremainder | 94.32% | 4.97M shares |
5.27M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (5.27M in the company's Sep 3, 2026 report, 4.30M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
David P. LuciInsiderdirector, 10 percent owner, officer: President and CEO | 1.04% | 54,873 | Form 4filed Jan 8, 2025 ↗ |
Jane Street Group, LLCInstitution | 1.04% | 54,642 | 13Fas of Mar 31, 2026 |
Robert J. DelucciaInsiderdirector, 10 percent owner | 0.96% | 50,510 | Form 4filed Jan 8, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 0.59% | 31,099 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.47% | 24,819 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Merck
Oral Dificid is a branded alternative for acute CDI treatment.
- ANI Pharmaceuticals
Vancocin and generic capsules are the pivotal-trial standard of care.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Acurx Pharmaceuticals | $1.42 | −1.05% | $6.1M | — | — | — | — |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| ANI Pharmaceuticals | $73.07 | +1.60% | $1.66B | 15.8 | 7.8 | 1.7 | +25.9% |
| Median | 68.5 | 12.7 | 3.7 | +15.5% |